Who are Recombinant Activated Factor VII's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eptacog alfa (NovoSeven), Intravenous infusions of Xyntha, OBIZUR, TachoSil, Kogenate (BAY14-2222), Fibrinogen + PCC.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/recombinant-activated-factor-vii.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Recombinant Activated Factor VII — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Recombinant Activated Factor VII (Recombinant Activated Factor VII) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Coagulation factor. Area: Hematology.

phase 3 Coagulation factor Tissue Factor (TF); Factor X Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Recombinant Activated Factor VII (Recombinant Activated Factor VII) — Hoffmann-La Roche. Recombinant Activated Factor VII (rFVIIa) directly activates the extrinsic coagulation pathway to promote thrombin generation and hemostasis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Recombinant Activated Factor VII TARGET	Recombinant Activated Factor VII	Hoffmann-La Roche	phase 3	Coagulation factor	Tissue Factor (TF); Factor X
Eptacog alfa (NovoSeven)	Eptacog alfa (NovoSeven)	Novo Nordisk A/S	marketed	Recombinant coagulation factor	Tissue factor (TF) / Factor X
Intravenous infusions of Xyntha	Intravenous infusions of Xyntha	Pfizer	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII
OBIZUR	OBIZUR	Baxalta now part of Shire	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII
TachoSil	THROMBIN	Corza Medical GmbH	marketed	Human Blood Coagulation Factor [EPC]
Kogenate (BAY14-2222)	Kogenate (BAY14-2222)	Bayer	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII
Fibrinogen + PCC	Fibrinogen + PCC	University Health Network, Toronto	marketed	Hemostatic agent / Coagulation factor replacement

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Coagulation factor class)

Hoffmann-La Roche · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Recombinant Activated Factor VII — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-activated-factor-vii. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing